Jan.22.2024
R & D
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Reduced the Risk of Disease Progression or Death by 79% Versus Chemotherapy in Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer in CheckMate -8HW Trial
This material is intended to notify the press release issued on January 20 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
Please click https://www.bms.com/media/press-releases.html for the original press release.